Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxurion NV

www.oxurion.com

Latest From Oxurion NV

Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema

The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.

 

Ophthalmic Clinical Trials

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

ThromboGenics Eyes Name Change To Oxurion

With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.

Business Strategies Ophthalmic
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • ThromboGenics NV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Oxurion NV
  • Senior Management
  • Patrick De Haes, MD, CEO
    Dominique Vanfleteren, CFO
    Stuart Laermer, CBO
    Susan Schneider, MD, ThromboGenics NV
    Vinciane Vangeersdaele, Chief Commercial Officer
  • Contact Info
  • Oxurion NV
    Phone: (32) 16 75 1310
    Gaston Geenslaan 1
    Heverlee, B-3001
    Belgium
UsernamePublicRestriction

Register